Clinical Trials in San Antonio

Showing 3781-3800 of 7,941 trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic \[Tc\] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.

COVID-19SARS-CoV2

SAb Biotherapeutics, Inc.28 participantsStarted Jul 2020

Wichita, Kansas, United States • Syracuse, New York, United States • San Antonio, Texas, United States

TERMINATEDPhase 1/2< 1 mile

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

NCT02880371

This is an open-label, multicenter Phase 1b/2 study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ARRY-382 in combination with pembrolizumab in adult patients with selected advanced solid tumors (Part A/Phase 1b); and to estimate the efficacy of the combination in three separate cohorts: 1) patients with advanced solid tumors that have progressed on prior PD-1/PD-L1inhibitors, 2) patients with platinum-resistant ovarian cancer and 3) patients with pancreatic ductal adenocarcinoma (Phase 2).

Advanced Solid Tumors

Pfizer82 participantsStarted Sep 2016

Los Angeles, California, United States • Los Angeles, California, United States • Santa Monica, California, United States +27 more locations

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

Find Trials by Condition in San Antonio

Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia

SHIELD II Clinical Investigation

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation

CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Surgical Idiopathic Intracranial Hypertension Treatment Trial

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

Esteem New Subject Enrollment Post Approval Study

Cooled RFA vs Conventional RFA to Manage Chronic Facetogenic Low Back Pain

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)

Renuvion Dermal System for Dermal Resurfacing

A Study of LY3540378 in Healthy Participants